Gemini
Senior Member
- Messages
- 1,176
- Location
- East Coast USA
[excerpt]
In 2020, we will launch a new study to examine the network connections between the metabolome and exposome. Using advanced machine learning and network dynamic analysis, this new study will help pave the way for the future suramin ME/CFS treatment trial.
Other exciting studies include a new collaboration with the brilliant virologist, Dr. Bhupesh Prusty at the University of Würzburg, Germany. Using a new, cell-based assay system, we are hot on the trail of both the identity and the biological control of the activity in ME/CFS blood that causes fatigue.
This “fatigue factor” looks like it could be the same thing that coordinates the mitochondrial and metabolic features of the cell danger response (CDR) and inflammation5, changes impedance in the nanoneedle10, inhibits recovery from illness by blocking the healing cycle9, induces a dauer-like state11, and triggers collagen remodeling over time that can cause acquired forms of Ehlers Danlos-like syndromes.
If successful, these studies will help fill in missing details in how suramin, copaxone, and elamipretide (SS31) might work to treat ME/CFS.
http://naviauxlab.ucsd.edu/wp-content/uploads/2019/12/Naviaux-Lab-Newsletter-Winter-2019_v10_sm.pdf
[my bold & paragraphing]
In 2020, we will launch a new study to examine the network connections between the metabolome and exposome. Using advanced machine learning and network dynamic analysis, this new study will help pave the way for the future suramin ME/CFS treatment trial.
Other exciting studies include a new collaboration with the brilliant virologist, Dr. Bhupesh Prusty at the University of Würzburg, Germany. Using a new, cell-based assay system, we are hot on the trail of both the identity and the biological control of the activity in ME/CFS blood that causes fatigue.
This “fatigue factor” looks like it could be the same thing that coordinates the mitochondrial and metabolic features of the cell danger response (CDR) and inflammation5, changes impedance in the nanoneedle10, inhibits recovery from illness by blocking the healing cycle9, induces a dauer-like state11, and triggers collagen remodeling over time that can cause acquired forms of Ehlers Danlos-like syndromes.
If successful, these studies will help fill in missing details in how suramin, copaxone, and elamipretide (SS31) might work to treat ME/CFS.
http://naviauxlab.ucsd.edu/wp-content/uploads/2019/12/Naviaux-Lab-Newsletter-Winter-2019_v10_sm.pdf
[my bold & paragraphing]